Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-06-28 07:00 |
Polyphor provides update on the Phase III FORTRESS study of balixafortide in pa…
|
English | 10.6 KB | ||
| 2021-06-08 07:30 |
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel…
|
English | 11.6 KB | ||
| 2021-06-01 07:30 |
Polyphor's balixafortide demonstrates consistent dual action anti-viral and ant…
|
English | 13.0 KB | ||
| 2021-05-18 07:30 |
Polyphor to present at the UBS Global Healthcare Virtual Conference
|
English | 8.7 KB | ||
| 2021-04-06 19:00 |
Polyphor Annual General Meeting 2021
|
English | 9.0 KB | ||
| 2021-03-15 07:30 |
Polyphor publishes invitation to Annual General Meeting 2021
|
English | 10.2 KB | ||
| 2021-03-05 07:15 |
Polyphor announces financial results for the full-year 2020
|
English | 24.4 KB | ||
| 2021-02-26 07:30 |
Polyphor to present full-year 2020 financial results on March 5
|
English | 8.5 KB | ||
| 2021-01-05 07:30 |
Polyphor to take part in panel discussion on novel oncology targets at the Life…
|
English | 8.4 KB | ||
| 2020-12-22 07:30 |
Polyphor receives approval to start first-in-human clinical trial of inhaled an…
|
English | 11.6 KB | ||
| 2020-12-14 07:30 |
Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommend…
|
English | 10.5 KB | ||
| 2020-12-11 07:30 |
Polyphor receives an additional USD 2.3 million award from CARB-X to support on…
|
English | 9.8 KB | ||
| 2020-11-24 07:30 |
Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundatio…
|
English | 11.4 KB | ||
| 2020-11-13 07:30 |
Polyphor to Host an Expert Perspectives Webinar on Innovative IO Approaches for…
|
English | 10.9 KB | ||
| 2020-10-29 07:30 |
Polyphor completes recruitment in Phase III trial of balixafortide in metastati…
|
English | 10.0 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
